John Konz

1.2k total citations
22 papers, 649 citations indexed

About

John Konz is a scholar working on Infectious Diseases, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, John Konz has authored 22 papers receiving a total of 649 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 13 papers in Cardiology and Cardiovascular Medicine and 10 papers in Molecular Biology. Recurrent topics in John Konz's work include Viral gastroenteritis research and epidemiology (16 papers), Viral Infections and Immunology Research (13 papers) and Virus-based gene therapy research (6 papers). John Konz is often cited by papers focused on Viral gastroenteritis research and epidemiology (16 papers), Viral Infections and Immunology Research (13 papers) and Virus-based gene therapy research (6 papers). John Konz collaborates with scholars based in United States, United Kingdom and Italy. John Konz's co-authors include Sangeetha L. Sagar, Jonathan King, C. L. Cooney, Ananda S Bandyopadhyay, Ann L. Lee, Rahnuma Wahid, Andrew Macadam, Ming Te Yeh, Raul Andino and John A. Lewis and has published in prestigious journals such as Nature, The Lancet and The Journal of Infectious Diseases.

In The Last Decade

John Konz

21 papers receiving 620 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Konz United States 13 376 280 272 165 98 22 649
Rita M. Meganck United States 12 216 0.6× 55 0.2× 341 1.3× 98 0.6× 63 0.6× 22 612
Hideki Nagano Japan 15 171 0.5× 57 0.2× 93 0.3× 64 0.4× 102 1.0× 64 666
Maja Šantak Croatia 16 190 0.5× 40 0.1× 169 0.6× 57 0.3× 299 3.1× 44 550
Mukti Kant Nayak India 17 516 1.4× 236 0.8× 92 0.3× 99 0.6× 80 0.8× 22 633
M A McKinlay United States 18 347 0.9× 754 2.7× 284 1.0× 72 0.4× 484 4.9× 24 1.1k
Maria Angela Biasolo Italy 16 182 0.5× 44 0.2× 216 0.8× 37 0.2× 330 3.4× 25 690
George R. Dubes United States 13 191 0.5× 177 0.6× 198 0.7× 115 0.7× 88 0.9× 50 510
Hilda Montero Mexico 12 222 0.6× 116 0.4× 148 0.5× 48 0.3× 123 1.3× 31 452
Jennifer Stencel-Baerenwald United States 9 239 0.6× 48 0.2× 195 0.7× 87 0.5× 153 1.6× 10 539
Liane Agulto United States 6 136 0.4× 60 0.2× 110 0.4× 48 0.3× 144 1.5× 9 493

Countries citing papers authored by John Konz

Since Specialization
Citations

This map shows the geographic impact of John Konz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Konz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Konz more than expected).

Fields of papers citing papers by John Konz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Konz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Konz. The network helps show where John Konz may publish in the future.

Co-authorship network of co-authors of John Konz

This figure shows the co-authorship network connecting the top 25 collaborators of John Konz. A scholar is included among the top collaborators of John Konz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Konz. John Konz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mercer, Laina D., Arlene C. Seña, E. Ross Colgate, et al.. (2025). Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial. The Lancet Infectious Diseases. 25(12). 1363–1376. 1 indexed citations
2.
3.
Yeh, Ming Te, Matthew R. Smith, Jennifer L. Konopka‐Anstadt, et al.. (2023). Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature. 619(7968). 135–142. 30 indexed citations
4.
Macklin, Grace, Corey M. Peak, Ondrej Mach, et al.. (2022). Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine. 41. A122–A127. 38 indexed citations
5.
Wahid, Rahnuma, Laina D. Mercer, Rodrigo DeAntonio, et al.. (2022). Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials. The Lancet Microbe. 3(12). e912–e921. 10 indexed citations
6.
Wahid, Rahnuma, et al.. (2022). Quantitative RT-PCR Assays for Quantification of Undesirable Mutants in the Novel Type 2 Oral Poliovirus Vaccine. Vaccines. 10(9). 1394–1394. 2 indexed citations
7.
Wahid, Rahnuma, Laina D. Mercer, Andrew Macadam, et al.. (2021). Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. npj Vaccines. 6(1). 94–94. 13 indexed citations
8.
Konz, John, Rahnuma Wahid, Jeroen R. P. M. Strating, et al.. (2021). Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. Vaccine X. 8. 100102–100102. 7 indexed citations
9.
10.
Coster, Ilse De, Isabel Leroux‐Roels, Ananda S Bandyopadhyay, et al.. (2020). Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. The Lancet. 397(10268). 39–50. 58 indexed citations
11.
Sáez‐Llorens, Xavier, Ananda S Bandyopadhyay, Christopher Gast, et al.. (2020). Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. The Lancet. 397(10268). 27–38. 55 indexed citations
12.
Yeh, Ming Te, Erika Bujáki, Patrick Dolan, et al.. (2020). Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host & Microbe. 27(5). 736–751.e8. 136 indexed citations
13.
Konz, John, et al.. (2008). Scaleable Purification of Adenovirus Vectors. Humana Press eBooks. 434. 13–23. 6 indexed citations
14.
Winters, Mark A., et al.. (2006). Sterilizing Filtration of Plasmid DNA: Effects of Plasmid Concentration, Molecular Weight, and Conformation. Biotechnology Progress. 22(2). 465–470. 17 indexed citations
15.
Goerke, Aaron R., Brian C.S. To, Ann L. Lee, Sangeetha L. Sagar, & John Konz. (2005). Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA. Biotechnology and Bioengineering. 91(1). 12–21. 32 indexed citations
16.
Altaras, Nedim Emil, John Auniņš, Robert K. Evans, et al.. (2005). Production and Formulation of Adenovirus Vectors. Advances in biochemical engineering, biotechnology. 99. 193–260. 65 indexed citations
17.
Konz, John, Ann L. Lee, John A. Lewis, & Sangeetha L. Sagar. (2005). Development of a Purification Process for Adenovirus: Controlling Virus Aggregation to Improve the Clearance of Host Cell DNA. Biotechnology Progress. 21(2). 466–472. 57 indexed citations
18.
Murphy, Jason C., et al.. (2005). Monitoring of RNA Clearance in a Novel Plasmid DNA Purification Process. Biotechnology Progress. 21(4). 1213–1219. 5 indexed citations
19.
Konz, John, et al.. (2005). Serotype Specificity of Adenovirus Purification Using Anion-Exchange Chromatography. Human Gene Therapy. 16(11). 1346–1353. 32 indexed citations
20.
Konz, John, et al.. (2005). Serotype Specificity of Adenovirus Purification Using Anion- Exchange Chromatography. Human Gene Therapy. 0(0). 3328902001–3328902001. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rita M. Meganck Breakdown of academic impact, for papers by Hideki Nagano Breakdown of academic impact, for papers by Maja Šantak Breakdown of academic impact, for papers by Mukti Kant Nayak Breakdown of academic impact, for papers by M A McKinlay Breakdown of academic impact, for papers by Maria Angela Biasolo Breakdown of academic impact, for papers by George R. Dubes Breakdown of academic impact, for papers by Hilda Montero Breakdown of academic impact, for papers by Jennifer Stencel-Baerenwald Breakdown of academic impact, for papers by Liane Agulto
Rankless by CCL
2026